Stock Price Movement and Market Context
On 2 Mar 2026, Sanofi India Ltd’s stock touched an intraday low of Rs.3848, representing a 2.91% decline on the day and a 2.87% drop in closing price. This marks the lowest price level for the stock in the past 52 weeks, down sharply from its 52-week high of Rs.6717.5. The stock has been on a three-day losing streak, cumulatively falling by 6.86% during this period.
In comparison, the Pharmaceuticals & Biotechnology sector outperformed Sanofi India by 2.32% on the same day, while the Sensex index, despite opening sharply lower by 2,743.46 points, managed a partial recovery to close at 79,947.11 points, down 1.65%. The Sensex remains below its 50-day moving average but maintains a positive trend with the 50DMA above the 200DMA.
Sanofi India’s share price currently trades below all key moving averages — 5-day, 20-day, 50-day, 100-day, and 200-day — signalling a persistent bearish momentum in the stock’s price action.
Just announced: This Small Cap from Tyres & Allied with precise target price is our pick for the week. Get the pre-market insights that informed this selection!
- - Just announced pick
- - Pre-market insights shared
- - Tyres & Allied weekly focus
Financial Performance and Growth Trends
Sanofi India Ltd has experienced a decline in key financial metrics over recent periods. The company’s net sales have contracted at an annualised rate of -8.74% over the last five years, while operating profit has decreased by -6.37% annually during the same timeframe. This long-term negative growth trajectory has contributed to the stock’s subdued performance.
In the most recent quarter ending December 2025, the company reported a net profit after tax (PAT) of Rs.61.70 crores, down 33.4% compared to the average of the previous four quarters. Net sales for the quarter stood at Rs.419.80 crores, reflecting a 13.1% decline versus the prior four-quarter average. The company’s profit before depreciation, interest, and taxes (PBDIT) was at a low of Rs.90.30 crores, underscoring the pressure on profitability.
Over the past year, Sanofi India’s stock has delivered a negative return of -22.93%, significantly underperforming the Sensex’s positive 9.19% gain. The stock has also lagged behind the BSE500 index over the last three years, one year, and three months, indicating persistent underperformance relative to broader market benchmarks.
Valuation and Efficiency Metrics
Despite the recent price weakness, Sanofi India exhibits some favourable financial characteristics. The company maintains a high return on equity (ROE) of 49.40%, reflecting strong management efficiency in generating shareholder returns. Additionally, the average debt-to-equity ratio remains at zero, indicating a debt-free capital structure.
The stock’s valuation appears attractive relative to its peers, trading at a price-to-book value of 11.7, which is considered very attractive given the company’s fundamentals. This valuation discount compared to historical peer averages may reflect market concerns over the company’s recent earnings decline and growth outlook.
At the current price level, Sanofi India offers a dividend yield of 4.84%, which is relatively high within the Pharmaceuticals & Biotechnology sector, providing a steady income component for shareholders.
Institutional investors hold a significant stake in the company, with 26.86% of shares owned by entities with greater analytical resources and long-term perspectives, which may influence the stock’s trading dynamics.
Holding Sanofi India Ltd from Pharmaceuticals & Biotechnology? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Summary of Key Metrics
Sanofi India Ltd’s current Mojo Score stands at 38.0, with a Mojo Grade of Sell, downgraded from Hold on 25 Feb 2026. The company’s market capitalisation grade is rated 3, reflecting moderate size and liquidity considerations.
The stock’s recent price action and financial results highlight a challenging environment for growth and profitability, with the share price reflecting these concerns through its 52-week low and underperformance relative to sector and market indices.
While the company’s strong management efficiency and low leverage provide some stability, the prevailing trend in sales and earnings has weighed on investor sentiment and valuation.
Market and Sector Comparison
Within the Pharmaceuticals & Biotechnology sector, Sanofi India’s recent underperformance contrasts with the broader sector’s relative resilience. The sector’s outperformance on the day of the stock’s 52-week low indicates selective pressures on Sanofi India’s shares rather than a sector-wide sell-off.
The Sensex’s partial recovery after a sharp gap down opening further emphasises that the stock’s decline is more company-specific, driven by its financial results and valuation concerns rather than general market weakness.
Conclusion
Sanofi India Ltd’s stock reaching a 52-week low of Rs.3848 on 2 Mar 2026 reflects a combination of subdued financial performance, declining sales and profits, and valuation pressures. The stock’s continued trading below all major moving averages and its downgrade to a Sell grade underscore the challenges faced by the company in recent periods. While certain financial metrics such as ROE and dividend yield remain favourable, the overall trend in earnings and share price performance has been negative over the past year and longer term.
Only Rs. 9,999 - Get MojoOne for 1 Year + 3 Months FREE (60% Off) Start Today
